News

The patient is expected to qualify for analytical treatment interruption of background anti-retroviral therapy.

Review top news and interview highlights from the week ending September 23, 2022.

The FDA previously lifted its clinical hold of the AFFINE study in May 2022.

The company previously presented positive preclinical data at the 2021 ASGCT meeting.

The professor of genetics at Federal University of Rio Grande do Sul discussed updated data from the CAMPSIITE trial.

Eleven patients in the LUMMICAR-2 trial were evaluable for preliminary efficacy analyses.

The chief medical officer of Triumvira Immunologics discussed updates from the TACTIC-2 study presented at ESMO Congress 2022.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

The FDA has cleared the investigational new drug application for AB-201.

Seven of 10 evaluable patients achieved minimal residual disease negativity after cilta-cel treatment.

Scientist have proposed several methods for converting stem cells into RPE, but there is still a gap in our knowledge of how cells respond to these stimuli over time.

The approval follows unanimous support of eli-cel's benefits in CALD from an FDA AdComm meeting and an approval for beti-cel in beta-thalassemia.

Administration of NTLA-2001 led to rapid and deep reductions in serum TTR by day 28.

Review top news and interview highlights from the week ending September 16, 2022.

A single-center study assessed the real-world experience of 20 patients treated with idecabtagene vicleucel with relapsed and refractory multiple myeloma who had exhausted at least 4 lines of prior therapy.

A substantial benefit noted for EtranaDez and val-rox is that they are delivered as a single-dose.

Nanoscope Therapeutics’ Phase 2 STARLIGHT open-label trial enrolled 6 subjects with advanced vision loss due to a clinical or genetic diagnosis of Stargardt disease.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

In nonclinical studies, AK-OTOF was well-tolerated in both mice and non-human primates.

The gene therapy received a conditional marketing approval in the European Union in August 2022.

MT026 had an overall response rate of 83.3% in a first-in-human, investigator-initiated trial.

The FDA authorized the natural killer cell therapy combo for compassionate use.

The 5-year relapse-free survival rate was 22.3% with T-VEC prior to surgery, compared with 15.2% for surgery alone.

Based on the findings, investigators are considering registration with the FDA and EMA.

ADP-A2M4CD8 will be evaluated in the phase 2 SURPASS-3 trial initiating in late 2022 or early 2023.

A phase 2 trial evaluated the therapy in patients with diffuse large B-cell lymphoma, B-acute lymphocytic leukemia, and follicular lymphoma.

Review top news and interview highlights from the week ending September 9, 2022.

BNT211 showed encouraging responses in testicular cancer but less encouraging responses in ovarian cancer.